Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 11, 2017

View Archived Issues

KIST presents novel drug candidate for Alzheimer's disease, KDS-2010

KemPharm reports preliminary data from phase I study of KP-415

First interim analysis of UNITY-NHL trial of TG-1101 and TGR-1202

PeptiDream, Shionogi and Sekisui to establish joint venture to manufacture special peptides

CARsgen's anti-Claudin18.2 CAR T-cell therapy begins phase I study

Cancer Research UK to collaborate with Biotecnol on development of novel immune-oncology drug

Radicava launched in U.S. for ALS

Mice bred to discover unknown genetic modifiers of familial Alzheimer's disease

NCI grant supports SignalRx's preclinical development of epigenetic-kinase inhibitors for cancer

Taiho Pharmaceutical begins enrolling patients in phase II study of TAC-302

Patient enrollment begins in phase I trial of CD33-CAR-T cell therapy in CD33-positive AML

FDA grants priority review to NDA for bictegravir/emtricitabine/tenofovir alafenamide in HIV

Takeda forms immuno-oncology research collaboration with Shattuck

New targets modifying tau pathology progression identified

Starpharma and Monash awarded funding from SIEF STEM+ Business Fellowship Program

EMERALD study bolsters darunavir, cobicistat, emtricitabine and tenofovir alafenamide fumarate

Novo Nordisk reviews key pipeline events of second quarter 2017

Chiasma reaches agreement with FDA on phase III trial of octreotide for acromegaly

Lundbeck reviews highlights of second quarter 2017

FDA accepts Achieve's IND for cytisine for smoking cessation

Yeda Research & Development patents protein LYRIC/transcription factor p65 interaction inhibitors

Beijing Marino Biotechnology describes a transgenic lymphocyte construct identifying EGFRvIII

Sumitomo Dainippon Pharma divulges new semaphorin-3A inhibitors

Guangzhou Institutes of Biomedicine and Health presents novel RORC antagonists

Novel orexin OX1 receptor antagonists discovered at C4X Discovery Holdings

Soin Neuroscience signs development agreement with Cleveland Diabetes Care for TV-1001sr

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...